High levels of UCHL1 predict poor outcomes in patients with GCB-DLBCL treated with R-CHOP. (A-C) PFS for all patients with paired gene expression and survival data from the International DLBCL Rituximab-CHOP Consortium Program study (n = 470) (A), those with ABC-DLBCL (n = 199) (B), and GCB-DLBCL (n = 227) (C). UCHL1 was stratified with LO (=0%-80%) HI (=80%-100%) based on the entire cohort. P values were determined using the Mantel-Cox log-rank test. (D) The level of MYC mRNA is shown for the entire cohort from panel A including those lacking survival data (n = 498). UCHL1 stratification as in panels A-C. P value was determined using the Student t test. (E-F) PFS of patients with GCB-DLBCL (n = 227) with paired gene expression and survival data based on the stratification of UCHL1 and MYC. UCHL1 was stratified as above. MYC was stratified with LO (=0%-75%) and HI (=75%-100%). Data extracted from GSE31312 and analyzed using the R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl).